Dataset Information
SU086 Treatment for Advanced Prostate Cancer
Ontology highlight
ABSTRACT:
INSTRUMENT(S): LTQ Orbitrap Elite
ORGANISM(S): Homo Sapiens (human)
TISSUE(S): Cell Culture
DISEASE(S): Prostate Cancer
SUBMITTER: 
Sharon Pitteri
LAB HEAD: Sharon Pitteri
PROVIDER: PXD030524 | Pride | 2022-04-01
REPOSITORIES: Pride
Dataset's files
| Action | DRS | |||
|---|---|---|---|---|
| Key.xlsx | Xlsx | |||
| MR17_040318_01.raw | Raw | |||
| MR17_040318_01.raw_20180411_Byonic_database.xlsx | Xlsx | |||
| MR17_040318_02.raw | Raw | |||
| MR17_040318_02.raw_20180411_Byonic_database.xlsx | Xlsx |
Items per page: 1 - 5 of 78 |
Publications
SU086, an inhibitor of HSP90, impairs glycolysis and represents a treatment strategy for advanced prostate cancer.
Cell reports. Medicine 20220202 2
Among men, prostate cancer is the second leading cause of cancer-associated mortality, with advanced disease remaining a major clinical challenge. We describe a small molecule, SU086, as a therapeutic strategy for advanced prostate cancer. We demonstrate that SU086 inhibits the growth of prostate cancer cells <i>in vitro</i>, cell-line and patient-derived xenografts <i>in vivo</i>, and <i>ex vivo</i> prostate cancer patient specimens. Furthermore, SU086 in combination with standard of care secon ...[more]
